LEGN: Legend Biotech Corporation
Performance
LEGN -23.62%
Watchlist
Select an item
Summary
LEGN at a glance
LEGN returned -23.62% over the past year and -12.96% a year over five years. Its worst drop in that year was -53.14%, smaller than 19% of stocks on Redstone, and its Sharpe ratio of -0.05 beats 25% of stocks on Redstone. It pays no dividends.
Current Drawdown
-33.05%
Rolling Volatility
57.06%
Actions
Metrics
Risk Indicators
Alpha-9.37%
Beta0.58x
Sharpe-0.05
Sortino-0.08
Omega0.99
Calmar-0.44
Martin-0.10
Profile
About LEGN
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma.
- Sector
- Health Care
- Market cap
- $4.7B
- Listed
- Jun 2020
- Employees
- 3,200
- Website
- legendbiotech.com
Comparisons